# A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Source: https://onco.cc/trials/nct05060016/  
OnCo record `nct05060016` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT05060016 by Amgen, with 222 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: Tarlatamab. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05060016
- Phase: 2
- Setting: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).
- Sponsor: Amgen
- Enrolled: 222

## Sources

- ClinicalTrials.gov NCT05060016: https://clinicaltrials.gov/study/NCT05060016

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct05060016.json